Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Change in Acquisitions & Divestments: 2024-2025

  • SAB Biotherapeutics' Change in Acquisitions & Divestments was N/A to $5.2 million in Q2 2025 from the same period last year, while for Jun 2025 it was $24.4 million, marking a year-over-year change of. This contributed to the annual value of $25.8 million for FY2024, which is N/A change from last year.
  • Per SAB Biotherapeutics' latest filing, its Change in Acquisitions & Divestments stood at $5.2 million for Q2 2025, which was up 10.72% from $4.7 million recorded in Q1 2025.
  • Over the past 5 years, SAB Biotherapeutics' Change in Acquisitions & Divestments peaked at $10.7 million during Q4 2024, and registered a low of $3.8 million during Q3 2024.
  • Its 2-year average for Change in Acquisitions & Divestments is $6.1 million, with a median of $5.0 million in 2025.